Cerebral Toxoplasmosis: Alternative Treatment When First-Line Therapy Fails or Is Not Tolerated
This protocol applies to patients with cerebral toxoplasmosis in whom the preferred first-line acute regimen has not produced the expected clinical or radiologic response, or cannot be continued because of drug intolerance.
When First-Line Therapy Falls Short
The preferred acute regimen — pyrimethamine plus sulfadiazine plus leucovorin, or TMP-SMX — is expected to produce neurological improvement within 14 days and measurable radiologic resolution of brain lesion(s), including reduction in size, contrast enhancement, and associated edema, at 3 and 6 weeks. Failure to reach these milestones, or intolerance of sulfadiazine, is the trigger for this alternative-regimen protocol.
Clinical Goals
The therapeutic targets are the same: neurological improvement by 14 days, and resolution of brain lesion(s) — assessed by size, contrast enhancement, and edema — on repeat imaging.
Alternative Regimen Approach
Several alternative acute regimens exist, each substituting one or more components of the preferred combination. Options vary for patients who cannot tolerate sulfadiazine, those who do not respond to the preferred regimen, and those with a history of sulfa allergy. The complete set of alternatives, with evidence ratings, is in the full protocol.
References
- (Pyrimethamine + leucovorin) plus clindamycin 600 mg IV or PO every 6 hours (AI); preferred alternative for patients intolerant of sulfadiazine or who do not respond to pyrimethamine-sulfadiazine; must add additional agent for PCP prophylaxis (AII).
- Atovaquone 1,500 mg PO twice daily + (pyrimethamine + leucovorin) (BII).
- Atovaquone 1,500 mg PO twice daily + sulfadiazine (BII).
- Atovaquone 1,500 mg PO twice daily (BII).
- For patients with a history of sulfa allergy, rapid sulfa desensitization may be attempted using one of several published strategies (BI).
- During the desensitization phase, atovaquone 1,500 mg PO should be administered twice daily until therapeutic doses of TMP-SMX (TMP 5 mg/kg and SMX 25 mg/kg) twice daily are achieved (CIII).
- Neurological improvement will occur by 14 days in over 90% of patients; if no improvement is seen by that time, other diagnoses should be considered.
- The radiologic goals for treatment include resolution of the lesion(s) in terms of size, contrast enhancement, and associated edema, although residual contrast-enhancing lesions may persist for prolonged periods, especially in people with HIV receiving ARVs.
View source ↗